A business in context

VRDN research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-08-19 · 0001193125-26-359636

  2. 4 · Ownership change

    Report date 2026-08-14 · 0001193125-26-355735

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001590750-26-000018

  4. 8-K · Current report

    Report date 2026-08-06 · 0001193125-26-336691 · Items 2.02,9.01

  5. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-294561

  6. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-294560

  7. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-294556

  8. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-294552

  9. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-294547

  10. 4 · Ownership change

    Report date 2026-07-01 · 0001193125-26-294546

  11. 8-K · Current report

    Report date 2026-06-26 · 0001193125-26-286273 · Items 7.01,8.01,9.01

  12. 8-K · Current report

    Report date 2026-06-02 · 0001193125-26-254560 · Items 5.07

  13. 8-K · Current report

    Report date 2026-05-27 · 0001193125-26-245186 · Items 1.02

  14. 8-K · Current report

    Report date 2026-05-24 · 0001193125-26-239246 · Items 1.01

  15. 8-K · Current report

    Report date 2026-05-06 · 0001193125-26-216709 · Items 1.01,2.03,8.01,9.01

  16. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001590750-26-000012

  17. 8-K · Current report

    Report date 2026-05-05 · 0001193125-26-205099 · Items 7.01,9.01

  18. 8-K · Current report

    Report date 2026-05-05 · 0001193125-26-205010 · Items 2.02,9.01

  19. DEF 14A · Proxy statement

    Report date 2026-06-02 · 0001193125-26-160344

  20. 8-K · Current report

    Report date 2026-03-30 · 0001193125-26-130433 · Items 7.01,9.01

  21. 10-K · Annual report

    Report date 2025-12-31 · 0001590750-26-000007

  22. 8-K · Current report

    Report date 2026-02-26 · 0001193125-26-073391 · Items 2.02,9.01

  23. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001590750-25-000020

  24. 8-K · Current report

    Report date 2025-11-05 · 0001193125-25-265711 · Items 2.02,9.01

  25. 8-K · Current report

    Report date 2025-10-21 · 0001193125-25-247410 · Items 1.01,9.01

  26. 8-K · Current report

    Report date 2025-10-21 · 0001193125-25-245206 · Items 2.02

  27. 8-K · Current report

    Report date 2025-10-17 · 0001193125-25-243039 · Items 1.01

  28. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001590750-25-000012

  29. 8-K · Current report

    Report date 2025-08-06 · 0001193125-25-173983 · Items 2.02,9.01

  30. 8-K · Current report

    Report date 2025-07-30 · 0001193125-25-168614 · Items 1.01,7.01,9.01

  31. 8-K · Current report

    Report date 2025-06-20 · 0001193125-25-145741 · Items 5.02,5.07,9.01

  32. 8-K · Current report

    Report date 2025-05-20 · 0001193125-25-122821 · Items 7.01,9.01

  33. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001590750-25-000008

  34. 8-K · Current report

    Report date 2025-05-06 · 0001193125-25-113291 · Items 2.02,9.01

  35. DEF 14A · Proxy statement

    Report date 2025-06-20 · 0001193125-25-095008

  36. 8-K · Current report

    Report date 2025-04-02 · 0001193125-25-073937 · Items 5.02,7.01,9.01

  37. 8-K · Current report

    Report date 2025-03-05 · 0001193125-25-050880 · Items 5.02

  38. 8-K · Current report

    Report date 2025-03-03 · 0001193125-25-044406 · Items 1.01,1.02,9.01

  39. 10-K · Annual report

    Report date 2024-12-31 · 0001590750-25-000004

  40. 8-K · Current report

    Report date 2025-02-27 · 0001193125-25-037586 · Items 2.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 2 transaction rows2SGrant / award: 6 transaction rows6AExercise / conversion: 4 transaction rows4MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

12 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-19
2026-08-20
Tousignant JenniferS · Sale
Disposed
Common Stock10000.024.5
2026-08-19
2026-08-20
Tousignant JenniferM · Exercise / conversion
Acquired
Common Stock10000.014.41
2026-08-19
2026-08-20
Tousignant JenniferS · Sale
Disposed
Common Stock4212.024.5
2026-08-19
2026-08-20
Tousignant JenniferM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
10000.00.0
2026-08-14
2026-08-18
Tripuraneni RadhikaM · Exercise / conversion
Acquired
Common Stock40000.013.21
2026-08-14
2026-08-18
Tripuraneni RadhikaM · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
40000.00.0
2026-07-01
2026-07-02
CAIN CHRISTOPHER W.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
32341.00.0
2026-07-01
2026-07-02
Ajer Jeffrey RobertA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
32341.00.0
2026-07-01
2026-07-02
Moses Jennifer K.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
32341.00.0
2026-07-01
2026-07-02
Gheuens SarahA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
32341.00.0
2026-07-01
2026-07-02
Kiselak TomasA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
32341.00.0
2026-07-01
2026-07-02
Morris ArleneA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
32341.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001590750Viridian Therapeutics, Inc.\DE

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • MIRAGEN THERAPEUTICS, INC. · former SEC name · 2017-02-13 to 2021-01-15
  • SIGNAL GENETICS, INC. · former SEC name · 2013-12-06 to 2017-02-10
  • SIGNAL GENETICS LLC · former SEC name · 2013-11-12 to 2014-07-09

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$302.0K$324.4K
2023-12-31$314.0K$347.2K
2022-12-31$1.77M$2.04M
2021-12-31$2.96M$3.68M
2020-12-31$1.05M$1.37M
2019-12-31$4.46M$5.88M
2018-12-31$8.39M$11.25M
2017-12-31$4.00M$5.50M

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗